Citigroup’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,439
Closed -$364K 6893
2020
Q4
$364K Buy
1,439
+820
+132% +$313K ﹤0.01% 4492
2020
Q3
$369K Buy
619
+295
+91% +$190K ﹤0.01% 4118
2020
Q2
$225K Buy
324
+48
+17% +$60.3K ﹤0.01% 4925
2020
Q1
$777K Buy
276
+20
+8% +$57.1K ﹤0.01% 3432
2019
Q4
$631K Buy
256
+92
+56% +$327K ﹤0.01% 4207
2019
Q3
$829K Buy
164
+9
+6% +$37.1K ﹤0.01% 3850
2019
Q2
$557K Buy
155
+44
+40% +$185K ﹤0.01% 4312
2019
Q1
$409K Sell
111
-12
-10% -$58.1K ﹤0.01% 4395
2018
Q4
$1.05M Sell
123
-54
-31% -$396K ﹤0.01% 3333
2018
Q3
$866K Sell
177
-8
-4% -$38.6K ﹤0.01% 3651
2018
Q2
$956K Buy
185
+179
+2,983% +$1.09M ﹤0.01% 3409
2018
Q1
$44K Buy
6
+2
+50% +$13.9K ﹤0.01% 6257
2017
Q4
$33K Sell
4
-1
-20% -$9.96K ﹤0.01% 6447
2017
Q3
$42K Buy
+5
New +$60.3K ﹤0.01% 6074

Other funds holding LABD

Citigroup's LABD Position: Q1 2025 in Review

Citigroup sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2025, closing a stake of 40 shares — an estimated $2.9K sold.

Citigroup first reported a position in LABD in Q2 2015 and held it in 29 quarters. The position peaked at $12.4M in Q2 2017. 14 funds tracked by Wall St. Rank hold LABD as of Q1 2025.

  • Citigroup reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 40 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2025, an estimated $2.9K.
  • Citigroup first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2015 and held it in 29 quarters.
  • Citigroup's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $12.4M in Q2 2017.
  • 14 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.